galectin-3 binding protein mimetic peptide

The galectin-3 binding protein (Gal3BP) mimetic peptide is a therapeutic agent designed to disrupt the interaction between Chitinase-3-like-1 (CHI3L1) and Galectin-3 (Gal3). In glioblastoma (GBM), the CHI3L1-Gal3 protein complex promotes an immunosuppressive tumor microenvironment by driving the migration and infiltration of protumor M2-like macrophages and activating PD-1/PD-L1 signaling. Gal3BP naturally competes with Gal3 for binding to CHI3L1, acting as a negative regulator of this immunosuppressive axis. The mimetic peptide recapitulates this competitive inhibition, leading to decreased M2-like macrophage migration, increased CD8+ T cell infiltration, and reduced expression of PD-L1 and PD-L2 in tumor cells. Developed by researchers at the University of Pittsburgh, this peptide has demonstrated the ability to inhibit tumor progression in both in vitro and in vivo glioblastoma models.

Other names

Gal3BP mimetic peptideGal-3BP mimetic peptideGal 3BP mimetic peptide